{"totalCount":4,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07155668","orgStudyIdInfo":{"id":"VRDN-003-304"},"organization":{"fullName":"Viridian Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","officialTitle":"A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED)"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-07","studyFirstSubmitQcDate":"2025-08-26","studyFirstPostDateStruct":{"date":"2025-09-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-13","lastUpdatePostDateStruct":{"date":"2026-01-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Viridian Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":true},"descriptionModule":{"briefSummary":"This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)","detailedDescription":"This is a randomized (meaning participants will be assigned to study arms by chance), open-label (meaning study doctor, participant and the sponsor will know which study arm participant is assigned to), parallel-group study that will enroll participants with TED of any duration. The key objectives of this study are to determine if VRDN-003 is safe and tolerable and to see how the body reacts to VRDN-003 when administered as a series of subcutaneous (SC) injections every 4 weeks or every 8 weeks in participants with TED either via autoinjector or via vial and syringe."},"conditionsModule":{"conditions":["Thyroid Eye Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized to one of the three study arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE","maskingDescription":"This is an open label study with no masking"}},"enrollmentInfo":{"count":87,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"VRDN-003 every 4 weeks using autoinjector","type":"EXPERIMENTAL","description":"6 subcutaneous administrations of VRDN-003 \\[1 loading dose of 600mg and 5 doses of 300mg\\]","interventionNames":["Drug: VRDN-003","Device: Autoinjector"]},{"label":"VRDN-003 every 8 weeks using autoinjector","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 \\[1 loading dose of 600mg and 2 doses of 300mg\\]","interventionNames":["Drug: VRDN-003","Device: Autoinjector"]},{"label":"VRDN-003 every 8 weeks using vial and syringe","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 \\[1 loading dose of 600mg and 2 doses of 300mg\\]","interventionNames":["Drug: VRDN-003"]}],"interventions":[{"type":"DRUG","name":"VRDN-003","description":"VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).","armGroupLabels":["VRDN-003 every 4 weeks using autoinjector","VRDN-003 every 8 weeks using autoinjector","VRDN-003 every 8 weeks using vial and syringe"]},{"type":"DEVICE","name":"Autoinjector","description":"The autoinjector is a single-dose, disposable, ready-to-use delivery device","armGroupLabels":["VRDN-003 every 4 weeks using autoinjector","VRDN-003 every 8 weeks using autoinjector"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment Emergent Adverse Event (TEAE) incidence rate","description":"Treatment Emergent Adverse Event (TEAE) incidence rate","timeFrame":"Through Week 24"}],"secondaryOutcomes":[{"measure":"Pharmacokinetic outcome measures","description":"Time of maximum serum concentration (Tmax) of VRDN-003","timeFrame":"Through Week 24"},{"measure":"Pharmacokinetic outcome measures","description":"Maximum serum concentration (Cmax) of VRDN-003","timeFrame":"Through Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a clinical diagnosis of TED with or without proptosis, with any CAS (0-7) and in the opinion of the Investigator may benefit from VRDN-003\n* Not require immediate ophthalmological or orbital surgery in the study eye for any reason\n* Must agree to use highly effective contraception as specified in the protocol\n* Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Must not have received prior treatment with another anti-IGF-1R therapy\n* Must not have received systemic corticosteroids for any condition, including TED, or selenium within 2 weeks prior to first dose.\n* Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED, within 12 weeks prior to first dose\n* Must not have received an investigational agent/device for any condition, including TED, within 8 weeks or longer (depending on the type of agent/device) prior to first dose\n* Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose\n* Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit\n* Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results\n* Must not have abnormal hearing test before first dose or history of ear conditions considered significant by study doctor\n* Must not have a history of inflammatory bowel disease\n* Female TED participants must not be pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"United Medical Research Institute","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"C&A Clinical Trials Corp","city":"Cape Coral","state":"Florida","zip":"33990","country":"United States","geoPoint":{"lat":26.56285,"lon":-81.94953}},{"facility":"Ilumina Medical Research","city":"Kissimmee","state":"Florida","zip":"34744","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Med-Care Research","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Continental Clinical Research, llc","city":"Miami","state":"Florida","zip":"33144","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Hype Clinical Research, LLC","city":"Miami","state":"Florida","zip":"33145","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Advanced Quality Medical Research, LLC","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Ophthalmic Consultants of Boston","city":"East Weymouth","state":"Massachusetts","zip":"02189","country":"United States","geoPoint":{"lat":42.21399,"lon":-70.92032}},{"facility":"Fraser Eye Center","city":"Fraser","state":"Michigan","zip":"48026","country":"United States","geoPoint":{"lat":42.5392,"lon":-82.94937}},{"facility":"Kahana Oculoplastic and Orbital Surgery","city":"Livonia","state":"Michigan","zip":"48152","country":"United States","geoPoint":{"lat":42.36837,"lon":-83.35271}},{"facility":"Vector Clinical Trials","city":"Sparks","state":"Nevada","zip":"89128","country":"United States","geoPoint":{"lat":39.53491,"lon":-119.75269}},{"facility":"Baylor College of Medicine, Alkek Eye Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Neuro Eye Clinical Trials INC","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D049970","term":"Graves Ophthalmopathy"}],"ancestors":[{"id":"D015785","term":"Eye Diseases, Hereditary"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006111","term":"Graves Disease"},{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D006042","term":"Goiter"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06625398","orgStudyIdInfo":{"id":"VRDN-003-302"},"organization":{"fullName":"Viridian Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","officialTitle":"REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","acronym":"REVEAL-2"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-10-01","studyFirstSubmitQcDate":"2024-10-02","studyFirstPostDateStruct":{"date":"2024-10-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-24","lastUpdatePostDateStruct":{"date":"2025-09-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Viridian Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).","detailedDescription":"This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.\n\nParticipants who do not have a meaningful response at Week 24 (irrespective of the initial treatment arm) may be eligible to receive additional subcutaneous injections of VRDN-003."},"conditionsModule":{"conditions":["Thyroid Eye Disease"],"keywords":["TED","Thyroid Eye Disease","Graves","Thyroid-Associated Ophthalmopathy","Dysthyroid Ophthalmopathy","Graves Eye Disease","Graves Orbitopathy","Myopathic Ophthalmopathy","Edematous Ophthalmopathy","Infiltrative Ophthalmopathy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized to one of the three study arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Participants will be randomized to one of the three study arms.","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":195,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"VRDN-003 every 4 weeks","type":"EXPERIMENTAL","description":"6 subcutaneous administrations of VRDN-003","interventionNames":["Drug: VRDN-003"]},{"label":"VRDN-003 every 8 weeks","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo","interventionNames":["Drug: VRDN-003","Drug: Placebo"]},{"label":"Placebo every 4 weeks","type":"PLACEBO_COMPARATOR","description":"6 subcutaneous administrations of placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"VRDN-003","description":"VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).","armGroupLabels":["VRDN-003 every 4 weeks","VRDN-003 every 8 weeks"]},{"type":"DRUG","name":"Placebo","description":"All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.","armGroupLabels":["Placebo every 4 weeks","VRDN-003 every 8 weeks"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Title: Proptosis Responder Rate in the study eye","description":"Description: Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\]","timeFrame":"At Week 24"}],"secondaryOutcomes":[{"measure":"Change from baseline in proptosis in the study eye","description":"Change from baseline in proptosis in the study eye","timeFrame":"At Week 24"},{"measure":"Overall Responder Rate in the study eye","description":"Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\] AND no worsening in CAS from baseline in the study eye \\[without a corresponding increase of ≥2 points in the fellow eye\\]","timeFrame":"At Week 24"},{"measure":"Diplopia Responder Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score of ≥1 from baseline (for participants with baseline Diplopia Score greater than 0)","timeFrame":"At Week 24"},{"measure":"Diplopia Resolution Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score to 0 from baseline (for participants with baseline Diplopia Score greater than 0)","timeFrame":"At Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Must have moderate to severe chronic TED, with any CAS (0-7) on the 7-item scale, and with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening\n* Must agree to use highly effective contraception as specified in the protocol\n* Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Must not have received prior treatment with another anti-IGF-1R therapy\n* Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose.\n* Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose\n* Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose\n* Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose\n* Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit\n* Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results\n* Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor\n* Must not have a history of inflammatory bowel disease\n* Female TED participants must not be pregnant or breastfeeding\n\nNOTE: There are additional eligibility criteria for participants who do not have a meaningful response at Week 24 (irrespective of initial treatment arm) who may receive additional injections of VRDN-003. These are described in the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Scottsdale Clinical Trials","city":"Scottsdale","state":"Arizona","zip":"85260","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Alliance Research Institute - Canoga Park","city":"Canoga Park","state":"California","zip":"91304","country":"United States","geoPoint":{"lat":34.20112,"lon":-118.59814}},{"facility":"Marvel Clinical Research","city":"Huntington Beach","state":"California","zip":"92647","country":"United States","geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"United Medical Research Institute","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"Advancing Research International, LLC","city":"Los Angeles","state":"California","zip":"90023","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Roski Eye Institute, Keck School of Medicine, USC","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Alliance Research Institute - Lynwood","city":"Lynwood","state":"California","zip":"90262","country":"United States","geoPoint":{"lat":33.93029,"lon":-118.21146}},{"facility":"A.P.J. Office","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Byers Eye Institute at Stanford University","city":"Palo Alto","state":"California","zip":"94303","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Pasadena Clinical Trials","city":"Pasadena","state":"California","zip":"91101","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Senta Clinic","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Ilumina Medical Research","city":"Kissimmee","state":"Florida","zip":"34744","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Med-Care Research","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Hype Clinical Research LLC","city":"Miami","state":"Florida","zip":"33145","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Anmed Health Services LLC","city":"Miami","state":"Florida","zip":"33193","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Southern Clinical Research LLc","city":"Miami","state":"Florida","zip":"33990","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Sarasota Retina Institute","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Agile Clinical Research Trials, LLC","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Vision Medical Research","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Massachusetts Eye and Ear","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Opthalmic Consultants of Boston","city":"East Weymouth","state":"Massachusetts","zip":"02189","country":"United States","geoPoint":{"lat":42.21399,"lon":-70.92032}},{"facility":"Fraser Eye Care Center","city":"Fraser","state":"Michigan","zip":"48026","country":"United States","geoPoint":{"lat":42.5392,"lon":-82.94937}},{"facility":"Kahana Oculoplastic & Orbital Surgery","city":"Livonia","state":"Michigan","zip":"48152","country":"United States","geoPoint":{"lat":42.36837,"lon":-83.35271}},{"facility":"University Health","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"S.L. Office","city":"Las Vegas","state":"Nevada","zip":"89144","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Vector Clinical Trials","city":"Sparks","state":"Nevada","zip":"89436","country":"United States","geoPoint":{"lat":39.53491,"lon":-119.75269}},{"facility":"Rutgers New Jersey Medical School","city":"Newark","state":"New Jersey","zip":"07103","country":"United States","geoPoint":{"lat":40.73566,"lon":-74.17237}},{"facility":"Asheville Clinical Research","city":"Asheville","state":"North Carolina","zip":"28803","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"facility":"Duke Eye Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Scheie Eye Institute Penn Presbyterian","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Wills Eye Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Horizon Clinical Research Group","city":"Cypress","state":"Texas","zip":"77429","country":"United States","geoPoint":{"lat":29.96911,"lon":-95.69717}},{"facility":"Baylor College of Medicine/Alkek Eye Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Gulf Coast Clinical Trials","city":"Houston","state":"Texas","zip":"77070","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Neuro-Eye Clinical Trials","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Washington, Eye institute","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"West Virginia University Eye Institute","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D049970","term":"Graves Ophthalmopathy"}],"ancestors":[{"id":"D015785","term":"Eye Diseases, Hereditary"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006111","term":"Graves Disease"},{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D006042","term":"Goiter"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06812325","orgStudyIdInfo":{"id":"VRDN-003-303"},"organization":{"fullName":"Viridian Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","officialTitle":"A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-02-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-01-27","studyFirstSubmitQcDate":"2025-01-31","studyFirstPostDateStruct":{"date":"2025-02-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-17","lastUpdatePostDateStruct":{"date":"2025-12-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Viridian Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).","detailedDescription":"This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), controlled study that will include participants with TED of any duration. The key objectives of this study are to determine if VRDN-003 is safe and tolerable when administered as a series of subcutaneous (SC) injections every 4 weeks or every 8 weeks in participants with TED."},"conditionsModule":{"conditions":["Thyroid Eye Disease (TED)"],"keywords":["Graves","Thyroid Eye Disease","Thyroid-Associated Ophthalmopathy","Dysthyroid Ophthalmopathy","Graves Eye Disease","Graves Orbitopathy","Myopathic Ophthalmopathy","Congestive Ophthalmopathy","Edematous Ophthalmopathy","Infiltrative Ophthalmopathy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized to one of the two study arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Participant, Site personnel (except pharmacy personnel preparing the injection), and Sponsor are masked.","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":321,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"VRDN-003 every 4 weeks","type":"EXPERIMENTAL","description":"6 subcutaneous administrations of VRDN-003","interventionNames":["Drug: VRDN-003"]},{"label":"VRDN-003 every 8 weeks","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo","interventionNames":["Drug: VRDN-003","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"VRDN-003","description":"VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).","armGroupLabels":["VRDN-003 every 4 weeks","VRDN-003 every 8 weeks"]},{"type":"DRUG","name":"Placebo","description":"Placebo injections that appear identical to VRDN-003 injections but have no active drug.","armGroupLabels":["VRDN-003 every 8 weeks"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24","description":"Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24","timeFrame":"Week 24"}],"secondaryOutcomes":[{"measure":"Change from baseline in proptosis in the study eye at Week 24 as measured by exophthalmometer","description":"Change from baseline in proptosis in the study eye","timeFrame":"Week 24"},{"measure":"TEAE incidence rate through Week 52","description":"Treatment Emergent Adverse Event (TEAE) incidence rate measurement through Week 52","timeFrame":"Week 52"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Have a clinical diagnosis of TED with or without proptosis and with any CAS (0-7) and in the opinion of the Investigator may benefit from VRDN-003\n* Not require immediate ophthalmological or orbital surgery in the study eye for any reason.\n* Must agree to use highly effective contraception as specified in the protocol\n* Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Must not have received prior treatment with another anti-IGF-1R therapy\n* Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose.\n* Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose\n* Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose\n* Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose\n* Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit\n* Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results\n* Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor\n* Must not have a history of inflammatory bowel disease\n* Female TED participants must not be pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Catalina Eye Care","city":"Tuscon","state":"Arizona","zip":"85712","country":"United States"},{"facility":"United Medical Research Institute","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"Orbital Plastics","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"California Eye Specialists Medical Group INC","city":"Pasadena","state":"California","zip":"91107","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"FOMAT Medical Research","city":"Pismo Beach","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":35.14275,"lon":-120.64128}},{"facility":"Pacific Neuroscience Institute","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"Pacific Neuroscience Institute at Saint John's Physician Partners","city":"Torrance","state":"California","zip":"90503","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"C A Clinical Trial Corp.","city":"Cape Coral","state":"Florida","zip":"33990","country":"United States","geoPoint":{"lat":26.56285,"lon":-81.94953}},{"facility":"Herco Medical and Research Center","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Alfa Medical Research","city":"Davie","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.06287,"lon":-80.2331}},{"facility":"D H Doral Research Center","city":"Doral","state":"Florida","zip":"33132","country":"United States","geoPoint":{"lat":25.81954,"lon":-80.35533}},{"facility":"Eye Centers of Florida","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Sina Medical Center","city":"Homestead","state":"Florida","zip":"33034","country":"United States","geoPoint":{"lat":25.46872,"lon":-80.47756}},{"facility":"East Coast Institute for Research, LLC","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Southern Clinical Research LLC","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Retreat Medical Research","city":"Miami","state":"Florida","zip":"33135","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Continental Clinical Research","city":"Miami","state":"Florida","zip":"33144","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Edward Jenner Research Group LLC","city":"Plantation","state":"Florida","zip":"33317","country":"United States","geoPoint":{"lat":26.13421,"lon":-80.23184}},{"facility":"Sarasota Retina Institute","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Advanced Quality Medical Research","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Ophthalmic Consultants of Boston","city":"East Weymouth","state":"Massachusetts","zip":"02189","country":"United States","geoPoint":{"lat":42.21399,"lon":-70.92032}},{"facility":"Fraser Eye Care Center","city":"Fraser","state":"Michigan","zip":"48026","country":"United States","geoPoint":{"lat":42.5392,"lon":-82.94937}},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"University of Missouri Kansas City","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Rutgers New Jersey Medical School","city":"Newark","state":"New Jersey","zip":"07103","country":"United States","geoPoint":{"lat":40.73566,"lon":-74.17237}},{"facility":"Jackson Clinic","city":"Jackson","state":"Tennessee","zip":"38305","country":"United States","geoPoint":{"lat":35.61452,"lon":-88.81395}},{"facility":"DFW Clinical Trials","city":"Carrollton","state":"Texas","zip":"75010","country":"United States","geoPoint":{"lat":32.95373,"lon":-96.89028}},{"facility":"Neuro Eye Clinical Trials","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Pioneer Research Solutions Inc.","city":"Houston","state":"Texas","zip":"77099","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"San Antonio Clinical Trials","city":"San Antonio","state":"Texas","zip":"78240","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Eyeplastx","city":"San Antonio","state":"Texas","zip":"78258","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Elevate Clinical Research","city":"Seabrook","state":"Texas","zip":"77586","country":"United States","geoPoint":{"lat":29.56412,"lon":-95.02548}},{"facility":"Servicde d'Endocrinologie, Diabetologieet Nutrition Centre Hospitalier Universitaire d'Angers","city":"Angers","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Abeillon du Payrat","city":"Bron","zip":"69500","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"Hôpital La Pitiélsalpêtrière","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Charite Universitatsmeizin Berlin KoR Campus Virchow Klinikum","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Universitatsklinikum Essen","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Universitaetsmedizin Goettingen","city":"Göttingen","zip":"37075","country":"Germany","geoPoint":{"lat":51.53443,"lon":9.93228}},{"facility":"Johannes Gutenberg University Medical Center Department of Medicine 1","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Okulistyki, Centrum Badań Klinicznych","city":"Bialystok","zip":"15-276","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Optimum Profesorskie Centrum Okulistyki Sp. z o. o.","city":"Gdansk","zip":"80-180","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Centrum Medyczne Pratia Gdynia","city":"Gdynia","zip":"81-338","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Santa Familia PTG Lodz","city":"Lodz","zip":"90-302","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"ETG Lublin","city":"Lublin","zip":"20-412","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Centrum Medyczne Pulawska Sp. z o.o.","city":"Piaseczno","zip":"05-500","country":"Poland","geoPoint":{"lat":52.0814,"lon":21.02397}},{"facility":"Warszawski Szpital Okulistyczny","city":"Warsaw","zip":"01-258","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Polimedica PTG","city":"Warsaw","zip":"02-777","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Hospital Provincial de Conxo","city":"A Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Institut Català de Retina","city":"Barcelona","zip":"08017","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital La Arruzafa","city":"Córdoba","zip":"14012","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hospital Universitario Ramon y Cajal","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Clinica Universidad de Navarre","city":"Navarrés","country":"Spain","geoPoint":{"lat":39.10198,"lon":-0.69469}},{"facility":"Hospital Universitario Virgen Macarena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Miguel Servet Consultas de Oftalmologia","city":"Zaragoza","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Gazi University Medical Faculty Hospital","city":"Ankara","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Hacettepe Univeristy Medical Fculty Hospital","city":"Ankara","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Akdeniz Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı","city":"Antalya","zip":"07059","country":"Turkey (Türkiye)","geoPoint":{"lat":36.90812,"lon":30.69556}},{"facility":"Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi Göz Hastalıkları Kliniği","city":"Istanbul","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"University Hospitals Bristol and Weston NHS Foundation Trust Clinical Research Unit","city":"Bristol","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"Addenbrookes Hospital","city":"Cambridge","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}},{"facility":"Imperial College Healthcare NHS Trust","city":"London","zip":"NW1 5QH","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Guy's and St Thomas' NHS Foundation Trust","city":"London","zip":"SE1 7EH","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Moorefields Eye Hospital NHS Foundation Trust","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"The Newcastle Upon Tyne Hospitals NHS Foundation Trust","city":"Newcastle","country":"United Kingdom","geoPoint":{"lat":54.21804,"lon":-5.88979}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D049970","term":"Graves Ophthalmopathy"}],"ancestors":[{"id":"D015785","term":"Eye Diseases, Hereditary"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006111","term":"Graves Disease"},{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D006042","term":"Goiter"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06625411","orgStudyIdInfo":{"id":"VRDN-003-301"},"organization":{"fullName":"Viridian Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)","officialTitle":"REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)","acronym":"REVEAL-1"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-10-01","studyFirstSubmitQcDate":"2024-10-02","studyFirstPostDateStruct":{"date":"2024-10-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-24","lastUpdatePostDateStruct":{"date":"2025-09-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Viridian Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).","detailedDescription":"This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with active TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as a series of subcutaneous/SC injections given every 4 weeks or every 8 weeks compared to placebo in participants with active TED.\n\nParticipants who do not have a meaningful response at Week 24 (irrespective of the initial treatment arm) may be eligible to receive additional subcutaneous injections of VRDN-003."},"conditionsModule":{"conditions":["Thyroid Eye Disease"],"keywords":["TED","Thyroid Eye Disease","Graves","Thyroid-Associated Ophthalmopathy","Dysthyroid Ophthalmopathy","Graves Eye Disease","Graves Orbitopathy","Myopathic Ophthalmopathy","Congestive Ophthalmopathy","Edematous Ophthalmopathy","Infiltrative Ophthalmopathy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized to one of the three study arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Participants, Investigator, Outcomes Assessor and Sponsor will be masked.","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":117,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"VRDN-003 every 4 weeks","type":"EXPERIMENTAL","description":"6 subcutaneous administrations of VRDN-003","interventionNames":["Drug: VRDN-003"]},{"label":"VRDN-003 every 8 weeks","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo","interventionNames":["Drug: VRDN-003","Drug: Placebo"]},{"label":"Placebo every 4 weeks","type":"PLACEBO_COMPARATOR","description":"6 subcutaneous administrations of placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"VRDN-003","description":"VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).","armGroupLabels":["VRDN-003 every 4 weeks","VRDN-003 every 8 weeks"]},{"type":"DRUG","name":"Placebo","description":"All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.","armGroupLabels":["Placebo every 4 weeks","VRDN-003 every 8 weeks"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proptosis Responder Rate in the study eye","description":"Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\]","timeFrame":"At Week 24"}],"secondaryOutcomes":[{"measure":"Change from baseline in proptosis in the study eye","description":"Change from baseline in proptosis in the study eye","timeFrame":"At Week 24"},{"measure":"Overall Responder Rate in the study eye","description":"Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\]) AND ≥ 2 points reduction in CAS from baseline in the study eye \\[without a corresponding increase of ≥2 points in the fellow eye\\]","timeFrame":"At Week 24"},{"measure":"Change from baseline in Clinical Activity Score (CAS) in the study eye","description":"Change from baseline in Clinical Activity Score (CAS) in the study eye \\[range, 0 to 7, with higher scores indicating greater level of inflammation\\]","timeFrame":"At Week 24"},{"measure":"Proportion of participants with a Clinical Activity Score (CAS) of 0 or 1 in the study eye","description":"Proportion of participants with a Clinical Activity Score (CAS) of 0 or 1 in the study eye","timeFrame":"At Week 24"},{"measure":"Diplopia Responder Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score of ≥1 from baseline (for participants with baseline Diplopia Score greater than 0","timeFrame":"At Week 24"},{"measure":"Diplopia Resolution Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score to 0 from baseline (for participants with baseline Diplopia Score greater than 0)","timeFrame":"At Week 24"},{"measure":"Clinical Activity Responder Rate in the study eye","description":"Clinical Activity Responder Rate in the study eye (i.e., ≥ 2 points reduction in CAS from baseline in the study eye \\[without a corresponding increase of ≥2 points in the fellow eye\\])","timeFrame":"At Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Must have moderate to severe active TED with documented evidence of ocular symptoms or signs that began within 15 months prior to screening\n* Must have a Clinical Activity Score (CAS) of ≥ 3 on the 7-item scale for the study eye\n* Must agree to use highly effective contraception as specified in the protocol\n* Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Must not have received prior treatment with another anti-IGF-1R therapy\n* Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose\n* Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose.\n* Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose\n* Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose\n* Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit\n* Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results\n* Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor\n* Must not have a history of inflammatory bowel disease\n* Female TED participants who must not be pregnant or breastfeeding\n\nNOTE: There are additional eligibility criteria for participants who do not have a meaningful response at Week 24 (irrespective of initial treatment arm) who may receive additional injections of VRDN-003. These are described in the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Scottsdale Clinical Trials","city":"Scottsdale","state":"Arizona","zip":"85260","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Alliance Research Institute - Canoga Park","city":"Canoga Park","state":"California","zip":"91304","country":"United States","geoPoint":{"lat":34.20112,"lon":-118.59814}},{"facility":"Marvel Clinical Research","city":"Huntington Beach","state":"California","zip":"92647","country":"United States","geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"United Medical Research Institute","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"Advancing Research International, LLC","city":"Los Angeles","state":"California","zip":"90023","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Roski Eye Institute, Keck School of Medicine, USC","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Alliance Research Institute - Lynwood","city":"Lynwood","state":"California","zip":"90262","country":"United States","geoPoint":{"lat":33.93029,"lon":-118.21146}},{"facility":"A.P.J. Office","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Byers Eye Institute at Stanford University","city":"Palo Alto","state":"California","zip":"94303","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Pasadena Clinical Trials","city":"Pasadena","state":"California","zip":"91101","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Senta Clinic","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"C&A Clinical Trials Corp","city":"Cape Coral","state":"Florida","zip":"33990","country":"United States","geoPoint":{"lat":26.56285,"lon":-81.94953}},{"facility":"Ilumina Medical Research","city":"Kissimmee","state":"Florida","zip":"34744","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Med-Care Research","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Continental Clinical Research","city":"Miami","state":"Florida","zip":"33144","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Hype Clinical Research LLC","city":"Miami","state":"Florida","zip":"33145","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Anmed Health Services LLC","city":"Miami","state":"Florida","zip":"33193","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Sarasota Retina Institute","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Agile Clinical Research Trials, LLC","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Vision Medical Research","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Opthalmic Consultants of Boston","city":"East Weymouth","state":"Massachusetts","zip":"02189","country":"United States","geoPoint":{"lat":42.21399,"lon":-70.92032}},{"facility":"Fraser Eye Care Center","city":"Fraser","state":"Michigan","zip":"48026","country":"United States","geoPoint":{"lat":42.5392,"lon":-82.94937}},{"facility":"Kahana Oculoplastic & Orbital Surgery","city":"Livonia","state":"Michigan","zip":"48152","country":"United States","geoPoint":{"lat":42.36837,"lon":-83.35271}},{"facility":"University Health","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"S.L. Office","city":"Las Vegas","state":"Nevada","zip":"89144","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Vector Clinical Trials","city":"Sparks","state":"Nevada","zip":"89436","country":"United States","geoPoint":{"lat":39.53491,"lon":-119.75269}},{"facility":"Rutgers New Jersey Medical School","city":"Newark","state":"New Jersey","zip":"07103","country":"United States","geoPoint":{"lat":40.73566,"lon":-74.17237}},{"facility":"Asheville Clinical Research","city":"Asheville","state":"North Carolina","zip":"28803","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"facility":"Duke Eye Center","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Baylor College of Medicine/Alkek Eye Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Gulf Coast Clinical Trials","city":"Houston","state":"Texas","zip":"77070","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Neuro-Eye Clinical Trials","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Washington, Eye institute","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"West Virginia University Eye Institute","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D049970","term":"Graves Ophthalmopathy"}],"ancestors":[{"id":"D015785","term":"Eye Diseases, Hereditary"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006111","term":"Graves Disease"},{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D006042","term":"Goiter"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false}
]}